Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels.Methods: A mul...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J. D. Ross, Bruce C. Carleton
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-09-01
Serie:	Frontiers in Pharmacology
Soggetti:	adverse drug reactions clinical implementation DPYD fluoropyrimidine toxicity pharmacogenetics
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1257745/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!